drugset / Trial / NCT06588530
PFAS Exposure and Immune Response to Vaccination in Adults
NaSingle-groupOpen-labelBasic science
Summary
This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine. The study focuses on participants from a community with known prior PFNA exposure through contaminated drinking water. The main question it aims to answer is: * Does exposure to PFNA weaken the body's initial immune response, leading to lower levels of protective antibodies after vaccination? Participants will: * Receive Tetanus and Diphtheria (Td) booster vaccination * Visit the study office 7 times over a 30-day period * Have blood and saliva collected at each study visit
Timeline
- Start
- 2024-11-04
- Primary completion
- 2025-01-08
- Completion
- 2025-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TENIVAC | Vaccine | 0.5 ml | Intramuscular |